CClinicalTrials.gg
RecruitingNCT06327581Updated Jan 26, 2026

Combined Microneedling With Either 1% Lactic Acid Solution or Vitamin D3 or Triamcinolone Acetonide in The Treatment of Alopecia Areata

An interventional study of Lactic Acid and vit D in Alopecia Areata, sponsored by Zagazig University. Recruiting at 1 site in Egypt. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-01-26.

Sponsored by Zagazig University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Dec 2023, registered Mar 2024).
  • Started Dec 2023; still recruiting 2 years 9 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Study summary

Alopecia areata (AA) is an immunologically mediated disease characterized by non-scarring hair loss (Madni and Shapiro, 2000). AA is presented by rapid and complete hair loss in one or more round or oval patches, usually on the scalp, beard area, eyebrows, eyelashes, and less commonly, on other hairy areas of the body (Berker et al., 2010 and James et al., 2011) Alopecia areata is a T-cell-mediated autoimmune disease. There is a complicated interplay between loss of immune privilege in the hair follicle, autoimmune-mediated hair follicle damage, and activation of inflammatory pathways that have been argued to explain the development of this disorder, but the exact pathophysiology of AA remains unknown. Hair follicles are infiltrated by autoreactive CD8 and CD4 T lymphocytes, which attack hair follicle-derived autoantigens while sparing the stem compartment (Rajabi et al., 2018).

Alopecia areata can be treated with topical and/or intralesional corticosteroids, which are the treatment of choice. Anthralin, minoxidil, coal tar, and topical immunotherapy are examples of other topical treatments. Systemic immunosuppressants such as cyclosporine, systemic steroids, Janus kinase inhibitors, and methotrexate may be considered in severe resistant cases (lee and lee, 2017).

Intralesional triamcinolone acetonide is preferred in cases of AA , as it is well known as anti-inflammatory and interferes with local immunity of the skin, which helps in the recovery of the disease, but if used in wrong technique or given in a high dose, it might cause all the side effects of corticosteroid, especially skin atrophy (Berker et al., 2010).

Lactic acid is a member of alpha-hydroxy acids. It has been used in the treatment of many skin diseases, like AA and vitiligo. Lactic acid stimulates spontaneous secretion of vascular endothelial growth factor (VEGF) by human reconstructed epidermis. VEGF is an angiogenic cytokine involved in angiogenesis and wound healing and stimulates the growth of hair follicles resulting in recovery of AA. Other studies suggest that lactic acid may act through its irritant effect (Al-Tammimy, 2005).

Vitamin D interacts with the innate and adaptive immune systems in a variety of ways, the majority of which contribute to its downregulation (Nancy and Yehuda, 2009). It has a powerful effect on T and B lymphocytes, influencing their activation responses (Arnson et al., 2007).

All cells of the immune system express 1,25-dihydroxyvitamin D3 receptors (VDRs) and are therefore vulnerable to calcitriol-mediated modulation. Vitamin D3 has the ability to influence the migration and maturation of different dendritic cell subtypes and their production of chemokines and cytokines, giving them an immunoregulatory and tolerogenic role (Illescas-Montes et al., 2019) It has been shown that VDRs are highly expressed in the keratinocytes of human hair follicles and the absence of their expression is associated with reduced hair follicle growth and epidermal differentiation. Reduced VDR expression in the hair follicles of affected areas has also been observed in studies of AA patients' scalp (Çerman et al., 2015).

Microneedling (MN) is a technique that comprises puncturing the skin repeatedly with sterile microneedles (Iriarte et al., 2017). It promotes hair regeneration by triggering stem cells in the hair bulge, which results in the generation of growth factors. It also improves blood circulation to the hair follicles and influences the local immune cells (Chandrashekar et al., 2014). Moreover, combining MN with applied topical drugs facilitates their absorption through the microchannels created within the epidermis (Fertig et al., 2018).

Read the detailed description

Patients in all groups will be subjected to microneedling (MN) using a dermapen "Dr.Pen") with adjustable needle length ranging from 1.5 to 2 mm, using the highest speed level (4-5). First, topical anesthetic cream will be applied. Then, they will be stroked by dermapen diagonally, vertically, and horizontally in a repeated manner until pinpoint bleeding appears which will be regarded as an endpoint.

  • First group (A): 22 AA patients will be treated with MN combined with lactic acid solution 1%. (Sharquis et al., 2015).
  • Second group (B): 22 AA patients will be treated with MN combined with topical application of vitamin D3 (an aqueous preparation of cholecalciferol (Devarol® ampoule 200 000 IU/2 ml, Memphis, Egypt) (2.5 mg/ ml), The maximum total amount of vitamin D3 injected into a patient in every session will be 2.5 mg (1 ml) (Ali et al., 2023).
  • Third group (C): 22 AA patients will be treated with MN combined with triamcinolone acetonide injectable suspension (Epirelefan®, 40mg/ ml, Eipico, Egypt) (10 mg/ml) will be used in a dose of 0.1 ml/cm2 area (Arora et al., 2022).
  • Fourth group (D): 22 AA patients will be treated with MN combined with normal saline 0.9% In all groups, sessions were done every 2 weeks for a maximum of six sessions. V. Photographs will be taken by (Iphone 13 pro max Camera) before, during and after treatment.
02

Conditions studied

  • Alopecia Areata

Browse trials for

03

In context

Alopecia Areata

467 studies on the registry are indexed under Alopecia Areata; 92 are open to participants now.

This study's planned enrollment of 88 is above the median of 50 across 380 interventional studies indexed under Alopecia Areata.

Browse Alopecia Areata studies →

Lead sponsor

Zagazig University is the lead sponsor of 447 studies on the registry; 75 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

    • Age ≥ 16 years old with localized patchy AA (up to 6 cm in diameter).

      • Patients of both sexes
      • Willing to participate in the study and to sign an informed consent.

Exclusion criteria

Exclusion Criteria:

    • Patients who received systemic or topical treatment for AA in the last 3 months prior to the start of the study

      • Patients with Alopecia totalis, universalis, ophiasis, or sisaipho
      • Pregnant or lactating females
      • Patients who had bleeding or coagulation disorders
      • Immunocompromised patients
      • Patients with known history of hypersensitivity to vit D
      • Patients taking vitamin D supplements in the last 6 months.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
88 participants (estimated)

Study arms

  • Experimental
    lactic acid group

    · First group (A): 22 AA patients will be treated with MN combined with lactic acid solution 1%.

    Drug: Lactic Acid

  • Experimental
    vitamin d3

    · Second group (B):22 AA patients will be treated with MN combined with topical application of vitamin D3 (an aqueous preparation of cholecalciferol (Devarol® ampoule 200 000 IU/2 ml, Memphis, Egypt) (2.5 mg/ ml), The maximum total amount of vitamin D3 injected into a patient in every session will be 2.5 mg (1 ml)

    Drug: vit D

  • Experimental
    triamcinolone acetonide group

    · Third group (C): 22 AA patients will be treated with MN combined with triamcinolone acetonide injectable suspension (Epirelefan®, 40mg/ ml, Eipico, Egypt) (10 mg/ml) will be used in a dose of 0.1 ml/cm2 area

    Drug: Triamcinolone Acetonide

  • Experimental
    saline

    · Fourth group (D): 22 AA patients will be treated with MN combined with normal saline 0.9%

    Drug: Saline

Interventions

  • DrugLactic Acid

    patients will be treated with MN combined with lactic acid solution 1%.

  • Drugvit D

    patients will be treated with MN combined with topical application of vitamin D3 (an aqueous preparation of cholecalciferol (2.5 mg/ ml), The maximum total amount of vitamin D3 injected into a patient in every session will be 2.5 mg (1 ml)

  • DrugTriamcinolone Acetonide

    patients will be treated with MN combined with triamcinolone acetonide injectable suspension (Epirelefan®, 40mg/ ml, Eipico, Egypt) (10 mg/ml) will be used in a dose of 0.1 ml/cm2 area

  • DrugSaline

    patients will be treated with MN combined with normal saline 0.9%

06

What researchers measure

Primary outcomes

  1. hair regrowth improvement assessed by SALT score and percaentage of hair growth

    Clinical scoring: The evaluation of therapeutic response will be carried out by three blinded investigators to determine the percentage of improvement as follows using SALT score and percentage of hair growth (A0 = no change or further hair loss, A1=1-24% regrowth, A2= 25-49%, A3=50-74%, A4= 75-99%, A5= 100% regrowth

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06327581
Lead sponsor
Zagazig University
Responsible party
Rana Ehab (lecturer of dermatology, Zagazig University) — Principal investigator
First posted
Mar 25, 2024
Start date
Dec 15, 2023
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Jan 26, 2026

Study contacts

rana ehab hamed ehab, md
Contact
ranaehab015@gmail.com
0201000896453
rana ehab, md
principal investigator · Zagazig University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion